Storia in 2 fonti

Novartis launches advanced-prostrate-cancer drug to India

Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision oncology options.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.com21 h fa

Novartis brings in its advanced-prostrate-cancer drug to India

Novartis launches Pluvicto, India's first regulatory-approved PSMA-targeted radioligand therapy for prostate cancer, targeting 250k annual cases with 50% metastatic presentations. The precision-oncology entry signals Novartis' emerging-market strategy and shift toward unlisted-subsidiary innovation.

Leggi questa versione → originale

economictimes.indiatimes.com22 h fa

Novartis India launches Pluvicto for prostate cancer treatment

Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer cells, offering a new treatment approach…

Leggi questa versione → originale

Timeline cronologica

lunedì 15 giugno 2026·economictimes.indiatimes.com
Novartis India launches Pluvicto for prostate cancer treatment
Novartis India has launched Pluvicto, the nation's first approved radioligand therapy for eligible prostate cancer patients. This precision radiotherapy precisely targets cancer…
lunedì 15 giugno 2026·thehindubusinessline.com
Novartis launches advanced-prostrate-cancer drug to India
Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision oncology options.
lunedì 15 giugno 2026·thehindubusinessline.com
Novartis brings in its advanced-prostrate-cancer drug to India
Novartis launches Pluvicto, India's first approved radioligand therapy for advanced prostate cancer, enhancing precision oncology options.